DETECTION OF PREPTIN AND MEGALIN IN TYPE 2 DIABETIC PATIENTS IN BAGHDAD CITY
Main Article Content
Keywords
Abstract
Type 2 Diabetes Mellitus is a common metabolic condition marked by high blood sugar caused by defective insulin secretion by pancreatic β-cells or insufficiency of insulin-sensitive tissues to respond appropriately to insulin due to environmental and genetic factors. Peptin is a peptide hormone that functions as a physiological regulator of insulin secretion mediated by glucose. Megalin is a glycoprotein mainly in the proximal tubular cells, primary function reabsorption of albumin and other proteins that the glomerulus filtered in the proximal tubules. The purpose of this research is to examine serum preptin and megalin levels in type 2 diabetics. in the period from December 2022 to March 2023 at the Baghdad Teaching Hospital.120 participants aged(30-60) years tested concentration of preptin, megalin, fasting blood glucose in serum and whole blood estimated for glycated hemoglobin (HbA1C).result indicates blood glucose concentration in patients with T2DM is (344.975±63.68) mg/dl was significantly higher than in control(106.62±12.59)mg/dl, and for HbA1C the average of patients is 13.40±10.35% was also significantly higher than control (4.310±0.336)% p < 0.001. preptin levels that the majority of patients with T2DM had the mean of (1076.10±208.72)pg/ml significantly higher than control (573.42±100.08)pg/ml. Megalin levels revealed that the mean for T2DM patients is (220.70±42.47) pg/ml significantly higher than control (120.42±29.33)pg/ml. According to the results, megalin and preptin levels were significantly increased in T2DM patients as compared to controls (P-value = 0.000). In conclusion, preptin and megalin may play a role in diabetes pathogenesis and biomarkers for early identification of diabetic nephropathy.
Downloads
References
[1] A. Artasensi, A. Pedretti, G. Vistoli, and L. Fumagalli, “Type 2 diabetes mellitus: a review of multi-target drugs,” Molecules, vol. 25, no. 8, p. 1987, 2020. [2] S. Palermi et al., “The complex relationship between physical activity and diabetes: An overview,” J. Basic Clin. Physiol. Pharmacol., vol. 33, no. 5, pp. 535–547, 2022. [3] N. Chaudhary and N. Tyagi, “Diabetes mellitus: An Overview,” Int. J. Res. Dev. Pharm. Life Sci., vol. 7, no. 4, pp. 3030–3033, 2018. [4] A. Andreadi et al., “Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease,” Int. J. Mol. Sci., vol. 24, no. 2, p. 1646, 2023. [5] T. I. Lodhi, “Diabetes Mellitus in Older Women,” Clin. Geriatr. Med., vol. 37, no. 4, pp. 491–507, 2021. [6] S. Wang et al., “Medium-and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study,” J. Pers. Med., vol. 13, no. 1, p. 21, 2022. [7] A. Bellia et al., “Exercise individualized by TRIMPi method reduces arterial stiffness in early onset type 2 diabetic patients: a randomized controlled trial with aerobic interval training,” Int. J. Cardiol., vol. 248, pp. 314–319, 2017. [8] M. Kałużna et al., “Is Preptin a New Bone Metabolism Parameter in Hemodialysis Patients?,” Life, vol. 11, no. 4, p. 341, 2021. [9] T. Anguilm et al., “Columbus State University Honors College: Senior Theses, Spring 2020,” 2020. [10] M. Cakir, S. Sabah Ozcan, M. Korkmaz, and S. Durusoy, “Decreased levels of plasma preptin in female patients with knee osteoarthritis,” 2019. [11] M. Kukida, H. Sawada, A. Daugherty, and H. S. Lu, “Megalin: a bridge connecting kidney, the renin-angiotensin system, and atherosclerosis,” Pharmacol. Res., vol. 151, p. 104537, 2020. [12] M. L. Nielsen et al., “Functional megalin is expressed in renal cysts in a mouse model of adult polycystic kidney disease,” Clin. Kidney J., vol. 14, no. 11, pp. 2420–2427, 2021. [13] A. Saito et al., “Role of megalin, a proximal tubular endocytic receptor, in the pathogenesis of diabetic and metabolic syndrome‐related nephropathies: protein metabolic overload hypothesis,” Nephrology, vol. 10, pp. S26–S31, 2005. [14] N. El Omri et al., “Evaluation of selected trace elements in the Moroccan type 2 diabetic patients,” 2020. [15] K. Bacos et al., “Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes,” Nat. Commun., vol. 7, no. 1, p. 11089, 2016. [16] N. Nanayakkara et al., “Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses,” Diabetologia, vol. 64, pp. 275–287, 2021. [17] C. Hu et al., “Association between age at diagnosis of type 2 diabetes and cardiovascular diseases: A nationwide, population-based, cohort study,” Front. Endocrinol. (Lausanne)., vol. 12, p. 717069, 2021. [18] A. S. Hassan, “Evaluation Iron (Fe) and lad (Pb) effect on Diabetes mellitus2 patients in Erbil Governorate,” Al-Nisour J. Med. Sci., vol. 4, no. 2, 2022. [19] S. Bahendeka, R. Wesonga, G. Mutungi, J. Muwonge, S. Neema, and D. Guwatudde, “Prevalence and correlates of diabetes mellitus in Uganda: a population‐based national survey,” Trop. Med. Int. Heal., vol. 21, no. 3, pp. 405–416, 2016. [20] D. Asiimwe, G. O. Mauti, and R. Kiconco, “Prevalence and risk factors associated with type 2 diabetes in elderly patients aged 45-80 years at Kanungu District,” J. Diabetes Res., vol. 2020, pp. 1–5, 2020. [21] K. W. Davidson et al., “Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement,” Jama, vol. 326, no. 8, pp. 736–743, 2021. [22] A. M. Ahmed, O. F. Khabour, A. H. Awadalla, and H. A. Waggiallah, “Serum trace elements in insulin-dependent and non-insulin-dependent diabetes: a comparative study,” Diabetes, Metab. Syndr. Obes. targets Ther., pp. 887–892, 2018. [23] A. Dutta, A. P. Dudhe, S. Deb, S. Dasgupta, and A. Sarkar, “A study on assessment of HbA1c level as a diagnostic criterion of type 2 diabetes mellitus,” Asian J. Med. Sci., vol. 7, no. 1, pp. 49–52, 2016. [24] D. Akselrod, M. Friger, and A. Biderman, “HbA1C variability among type 2 diabetic patients: a retrospective cohort study,” Diabetol. Metab. Syndr., vol. 13, pp. 1–7, 2021. [25] M. Kalayci, I. Halifeoglu, H. Kalayci, K. Ugur, and M. Yilmaz, “Plasma preptin levels in patients with type 2 diabetes mellitus,” Int. J. Med. Biochem., vol. 2, no. 1, pp. 1–5, 2019. [26] F. Faris Rija, M. I. Sulaiman Musa, and H. T. Hamad, “Some Biochemical Parameters and Level of Preptin in Newly Diagnosed Type 2 Diabetic Women Patients in Tikrit City,” J. Chem. Heal. Risks, vol. 12, no. 2, pp. 179–182, 2022. [27] A. Abbas, H. A. Ali, M. M. AL-Rufaie, and R. A. Ali, “Association of serum preptin levels with insulin resistance in Iraqi women with gestational diabetes mellitus,” Int Res J Pharm, vol. 10, pp. 49–55, 2019. [28] M. A. Bryniarski et al., “Increased megalin expression in early type 2 diabetes: role of insulin-signaling pathways,” Am. J. Physiol. Physiol., vol. 315, no. 5, pp. F1191–F1207, 2018. [29] M. Marzolo and P. Farfán, “New Insights into the Roles of Megalin / LRP2 and the Regulation of its Functional Expression,” pp. 89–105, 2011. [30] W. R. Alfatlawi, “Aldabagh et al ( 2021 ): Cubilin and megalin levels in association with vitamin D status © Annals of Tropical Medicine & Public Health Evaluation of Cubilin and Megalin levels in ass ... Evaluation of Cubilin and Megalin levels in association with vitamin D status in Iraqi patient with DM2,” no. April, pp. 40–45, 2021, doi: 10.36295/ASRO.2021.24508. [31] “Signi fi cance of Urinary Full-Length and With Type 2 Diabetes,” vol. 35, 2012, doi: 10.2337/dc11-1684. [32] S. De et al., “Exocytosis-mediated urinary full-length megalin excretion is linked with the pathogenesis of diabetic nephropathy,” Diabetes, vol. 66, no. 5, pp. 1391–1404, May 2017, doi: 10.2337/db16-1031.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.